• Phase 2 study initiated investigating the company’s Toll-Like Receptor 7 and 8 co-agonist, EIK1001
  • Enrolling patients in Phase 1 trial of highly selective PARP1 inhibitor, EIK1003
  • IND-enabling studies initiated for brain-penetrant selective PARP1 inhibitor, IMP17307
  • Additional clinical candidate expected to be identified in early 2024
  • Eikon Systems business unit established to provide access to proprietary technology

HAYWARD, Calif. – JANUARY 8, 2024 – Eikon Therapeutics, Inc., a pioneering biotechnology company that leverages advanced engineering to enhance drug discovery and development, today announced that the company will provide an overview of clinical and preclinical progress in a presentation at the 42nd Annual J.P. Morgan Healthcare Conference on Monday, January 8th at 9:00 AM Pacific Time.

“Eikon has made enormous progress in the development of advanced imaging tools that aid the discovery of important new therapeutics. Our clinical pipeline now includes an immunomodulatory agent, active both by itself and in combination with PD-(L)1 inhibitors, which is entering global Phase 2 studies, as well as a highly selective PARP1 inhibitor for which a Phase 1 program is now enrolling appropriate patients,” said Roger M. Perlmutter, M.D., Ph.D., CEO and Board Chair of Eikon Therapeutics. “Beyond these important clinical studies, we have a set of promising development candidates that are expected to advance into the clinic over the next 12 to 24 months. Our progress showcases the integrated clinical development capabilities of Eikon’s team and demonstrates that our proprietary instruments can identify novel chemical matter with especially desirable pharmaceutical properties. These achievements offer the promise of improved treatment outcomes in cancer patients, and in patients afflicted with intractable inflammatory or neurodegenerative conditions.”

Key updates:

  • EIK1001 Advances to Phase 2: Eikon’s most advanced candidate, EIK1001, a systemically administered TLR 7 and 8 co-agonist, has received Investigational New Drug Application (IND) clearance from the U.S. Food and Drug Administration (FDA) and has proceeded into the first of several planned Phase 2 trials focused, in this case, on patients with advanced lung cancer when administered in combination with standard-of-care pembrolizumab plus chemotherapy. The Phase 2 investigation of EIK1001 is supported by compelling data from a Phase 1 trial of over 300 patients, demonstrating its promise both as a standalone agent and in rational combinations with PD-(L)1 inhibitors.
  • EIK1003 Now Enrolling Patients: Eikon’s selective PARP1 inhibitor, EIK1003, has entered a Phase 1/2 clinical trial at multiple U.S. sites assessing safety and tolerability in adult patients that have received at least one prior PARP inhibitor treatment for specific solid tumors expressing selected deleterious genetic mutations. International sites will join the trial early in 2024. Preclinical studies of EIK1003 (formerly IMP1734) have shown remarkable biochemical and cellular selectivity, positioning it as a potential therapeutic option with less hematologic toxicity when compared to existing PARP1/2 inhibitors. This program is led by Eikon with its collaboration partner, Impact Therapeutics, which is responsible for trial oversight in greater China.
  • IND-enabling Studies Begin for Brain-Penetrant PARP1 Inhibitor, IMP17307: Collaborating with Impact Therapeutics, Eikon has initiated IND-enabling studies for a brain-penetrant PARP1 candidate and is planning for a Phase 1 clinical trial in 2025.
  • Discovery Pipeline Progress: Using its proprietary platform, Eikon is conducting lead optimization for several programs including those targeting the androgen receptor and its clinically relevant variants, as well as several targeting key proteins in the DNA damage repair pathway including Werner (WRN). The company anticipates nominating a new clinical candidate in early 2024.
  • Eikon Systems Business Unit Established: Eikon has developed a suite of instruments that permits detailed, automated characterization of protein motion in living cells. Since most proteins function by interacting with other cellular structures (including other proteins), analysis of the dynamic behavior of individual protein molecules yields information regarding the function and regulation of biologic systems. These tools are increasingly sought after by academic investigators through Eikon’s Technology Access Program. The company expects that instruments from Eikon Systems will help to catalyze the use of protein motion measurements routinely as a means of elucidating biological processes.

To access an audio recording of Eikon’s presentation at the 42nd Annual J.P. Morgan Healthcare Conference on Monday, January 8th, 2024, please click here.

About Eikon Therapeutics

Eikon Therapeutics seeks to advance breakthrough therapeutics through the purposeful integration of engineering and science. Our proprietary discovery technologies leverage Nobel Prize-winning super-resolution microscopy, advanced engineering, and high-performance computing to visualize and measure the real-time movement of proteins in living cells, with the goal of bringing important new medicines to people suffering from grievous illness. Eikon operates from its facilities in California, New Jersey, and New York and can be found online via our website or LinkedIn.